SpringerLink
Log in

Antiresorptive Drugs’ Role in Management of Postmenopausal Osteoporosis

  • Living reference work entry
  • First Online:
Bone Metabolism, Parathyroid Glands, and Calciotropic Hormones

Part of the book series: Endocrinology ((ENDOCR))

  • 10 Accesses

Abstract

Postmenopausal osteoporosis is a very common bone metabolic disorder, characterized by low bone mineral density, impairment of bone microarchitecture, and increased fractures risk. The primary cause of body mineral density reduction is the lack of estrogens, especially in 3–5 years after the onset of menopause. Fragility fractures due to postmenopausal osteoporosis are usually associated to significant burden, high healthcare expenses, and increased morbidity. Postmenopausal women at increased risk of fracture are typically chosen as the population for the pivotal studies on antifracture treatment. This chapter focuses on all antiresorptive drugs currently available for pharmacological management of postmenopausal osteoporosis. The most important challenge is to identify women affected by postmenopausal osteoporosis who need to be treated, considering efficacy, risk profile, cost-effectiveness of antiresorptive drugs, and clinical features of patient. However, although significant benefits of antiresorptive drugs have been widely demonstrated, these treatments are frequently under-prescribed also in postmenopausal osteoporosis, issue which should be resolved as much as possible in the next future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Abbreviations

AFFs:

atypical subtrochanteric fractures

aBMD:

areal BMD

ASBMR:

American Society for Bone and Mineral Research

ATP:

adenosine triphosphate

BMD:

bone mineral density

FDA:

Food and Drug Administration

GFR:

glomerular filtration rate

ONJ:

osteonecrosis of the jaw

PPi:

inorganic pyrophosphate

RANKL:

receptor activator of nuclear factor-κB ligand

SERMs:

selective estrogen-receptor modulators

TNF:

tumor necrosis factor

References

  • Adams AL, Adams JL, Raebel MA, Tang BT, Kuntz JL, Vijayadeva V, McGlynn EA, Gozansky WS. Bisphosphonate drug holiday and fracture risk: a population-based cohort study. J Bone Miner Res. 2018;33:1252–9. https://doi.org/10.1002/jbmr.3420.

    Article  PubMed  CAS  Google Scholar 

  • Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31:16–35. https://doi.org/10.1002/jbmr.2708.

    Article  PubMed  CAS  Google Scholar 

  • Axelsson KF, Wallander M, Johansson H, Lundh D, Lorentzon M. Hip fracture risk and safety with alendronate treatment in the oldest-old. J Intern Med. 2017;282:546e59. https://doi.org/10.1111/joim.12678.

    Article  CAS  Google Scholar 

  • Barrett-Connor E, Mosca L, Collins P, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in post-menopausal women. N Engl J Med. 2006;355:125e37. https://doi.org/10.1056/NEJMoa062462.

    Article  Google Scholar 

  • Barrionuevo PM, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, Almasri J, Farah W, Sarigianni M, Muthusamy K, Nofal AA, Haydour Q, Wang Z, Mohammad Hassan Murad MH. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104:1623–30. https://doi.org/10.1210/jc.2019-00192.

    Article  PubMed  Google Scholar 

  • Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet (London, England). 1996;348:1535e41. https://doi.org/10.1016/s0140-6736(96)07088-2.

    Article  Google Scholar 

  • Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group. Effects of continuing or stop** alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38. https://doi.org/10.1001/jama.296.24.2927.

    Article  PubMed  CAS  Google Scholar 

  • Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Fink Eriksen E, Cummings SR, HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809e22. https://doi.org/10.1056/NEJMoa067312.

    Article  Google Scholar 

  • Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzycky ME, Su G, Eastell R. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243–54. https://doi.org/10.1002/jbmr.1494.

    Article  PubMed  CAS  Google Scholar 

  • Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30:934–44. https://doi.org/10.1002/jbmr.2442.

    Article  PubMed  CAS  Google Scholar 

  • Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513e23. https://doi.org/10.1016/S2213-8587(17)30138-9.

    Article  Google Scholar 

  • Boonen S, Ferrari S, Miller PD. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk – a perspective. J Bone Miner Res. 2012;27(5):963–74. https://doi.org/10.1002/jbmr.1570.

    Article  PubMed  CAS  Google Scholar 

  • Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(Suppl 1):1–46. https://doi.org/10.4158/GL-2020-0524SUPPL.

    Article  PubMed  Google Scholar 

  • Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010;304:657–63. https://doi.org/10.1001/jama.2010.1098.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Cooper C, Reginster J-Y, Cortet B, Diaz-Curiel M, Lorenc RS, Kanis JA, Rizzoli R. Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin. 2012;28(3):475–91. https://doi.org/10.1185/03007995.2012.663750.

    Article  PubMed  CAS  Google Scholar 

  • Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570e8. https://doi.org/10.1210/er.2001-9002.

    Article  CAS  Google Scholar 

  • Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–82. https://doi.org/10.1001/jama.280.24.2077.

    Article  PubMed  CAS  Google Scholar 

  • Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA. 1999;281:2189e97. https://doi.org/10.1001/jama.281.23.2189.

    Article  Google Scholar 

  • Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756e65. https://doi.org/10.1056/NEJMoa0809493.

    Article  CAS  Google Scholar 

  • Cummings SR, Ferrari S, Eastell R, Gilchrist N, Beck Jensen JE, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33:190e8. https://doi.org/10.1002/jbmr.3337.

    Article  CAS  Google Scholar 

  • Deardorff WJ, Cenzer I, Nguyen B, Lee SJ. Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(1):33–41. https://doi.org/10.1001/jamainternmed.2021.6745.

    Article  PubMed  CAS  Google Scholar 

  • Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003;33:522e32. https://doi.org/10.1016/s8756-3282(03)00241-2.

    Article  Google Scholar 

  • Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004;15:792e8. https://doi.org/10.1007/s00198-004-1602-9.

    Article  CAS  Google Scholar 

  • Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54:1838e46. https://doi.org/10.1002/art.21918.

    Article  CAS  Google Scholar 

  • Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45. https://doi.org/10.4065/83.9.1032.

    Article  PubMed  CAS  Google Scholar 

  • Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–622. https://doi.org/10.1210/jc.2019-00221.

    Article  PubMed  Google Scholar 

  • Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene. Evaluation (MORE) Investigators. JAMA. 1999;282:637e45. https://doi.org/10.1001/jama.282.7.637.

    Article  Google Scholar 

  • Gatti D, Fassio A. Pharmacological management of osteoporosis in postmenopausal women: the current state of the art. J Popul Ther Clin Pharmacol. 2019;26:e1–e17. https://doi.org/10.15586/jptcp.v26.i4.646.

    Article  PubMed  Google Scholar 

  • Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. 2010;341:c4444. https://doi.org/10.1136/bmj.c4444.

  • Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA. 1999;282:1344e52. https://doi.org/10.1001/jama.282.14.1344.

    Article  Google Scholar 

  • Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24:237e45. https://doi.org/10.1185/030079908x253717.

    Article  Google Scholar 

  • Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1):136. https://doi.org/10.1007/s11657-013-0136-1.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, Hiligsmann M, Rizzoli R, Cooper C. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int. 2012;23:213–21. https://doi.org/10.1007/s00198-011-1796-6.

    Article  PubMed  CAS  Google Scholar 

  • Kanis JA, Borgström F, Compston J, Dreinhöfer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R, Stenmark J. SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos. 2013a;8:144. https://doi.org/10.1007/s11657-013-0144-1.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013b;24:23e57. https://doi.org/10.1007/s00198-012-2074-y.

    Article  Google Scholar 

  • Kanis JA, Cooper C, Rizzoli R, Reginster J-Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int. 2019;104:235–8. https://doi.org/10.1007/s00223-018-00512-x.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • von Keyserlingk C, Hopkins R, Anastasilakis A, Toulis K, Goeree R, Tarride JE, **e F. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum. 2011;41:178e86. https://doi.org/10.1016/j.semarthrit.2011.03.005.

    Article  CAS  Google Scholar 

  • Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom. 2017;20(1):8–24. https://doi.org/10.1016/j.jocd.2016.09.005.

    Article  PubMed  Google Scholar 

  • LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;2022(33):2049–102. https://doi.org/10.1007/s00198-021-05900-y.

    Article  Google Scholar 

  • Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799e809. https://doi.org/10.1056/NEJMoa074941.

    Article  Google Scholar 

  • McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med. 2001;344:333e40. https://doi.org/10.1056/NEJM200102013440503.

    Article  Google Scholar 

  • Meier C, Uebelhart B, Aubry-Rozier B, Birkhäuser M, Bischoff-Ferrari HA, Frey D, Kressig RW, Lamy O, Lippuner K, Stute P, Suhm N, Ferrari S. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss Med Wkly. 2017;147:w14484. https://doi.org/10.4414/smw.2017.14484. eCollection 2017

    Article  PubMed  CAS  Google Scholar 

  • Miller PD, Recker RR, Harris S, Silverman S, Felsenberg D, Reginster J, Day BM, Barr C, Masanauskaite D. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int. 2014;25:349e57. https://doi.org/10.1007/s00198-013-2518-z.

    Article  CAS  Google Scholar 

  • Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R. Response of bone turnover markers to three oral bisphosphonate therapies in post- menopausal osteoporosis: the TRIO study. Osteoporos Int. 2016;27(1):21–31. https://doi.org/10.1007/s00198-015-3145-7.

    Article  PubMed  CAS  Google Scholar 

  • Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int. 2018;29(6):1407–17. https://doi.org/10.1007/s00198-018-4460-6.

    Article  PubMed  CAS  Google Scholar 

  • NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785–95. https://doi.org/10.1001/jama.285.6.785.

    Article  Google Scholar 

  • Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010;25(1):2–10. https://doi.org/10.1359/jbmr.091201.

    Article  PubMed  CAS  Google Scholar 

  • Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int. 2000;11:83e91. https://doi.org/10.1007/s001980050010.

    Article  Google Scholar 

  • Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654e61. https://doi.org/10.1136/ard.2005.044958.

    Article  CAS  Google Scholar 

  • Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379:2407–16. https://doi.org/10.1056/NEJMoa1808082.

    Article  PubMed  CAS  Google Scholar 

  • Rizzoli R. Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM. 2011;104(4):281–300. https://doi.org/10.1093/qjmed/hcq259.

    Article  PubMed  CAS  Google Scholar 

  • Rizzoli R. Postmenopausal osteoporosis: assessment and management. Best Pract Res Clin Endocrinol Metab. 2018;32(5):739–57. https://doi.org/10.1016/j.beem.2018.09.005.

    Article  PubMed  Google Scholar 

  • Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC 2nd, Kaur A, Peverly CA, Orloff JJ, Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002;17:1988e96. https://doi.org/10.1359/jbmr.2002.17.11.1988.

    Article  Google Scholar 

  • Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European society on clinical and economic aspects of osteoporosis and osteoarthritis, and international osteoporosis foundation working group report. Osteoporos Int. 2011a;22:373–90.

    Article  PubMed  CAS  Google Scholar 

  • Rizzoli R, Reginster JY, Boonen S, Breart G, Diez-Perez A, Felsenberg D, Kaufman JM, Kanis JA, Cooper C. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011b;89:91–104. https://doi.org/10.1007/s00223-011-9499-8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Rizzoli R, Branco J, Brandi ML, Boonen S, Bruyère O, Cacoub P, Cooper C, Diez-Perez A, Duder J, Fielding RA, Harvey NC, Hiligsmann M, Kanis JA, Petermans J, Ringe JD, Tsouderos Y, Weinman J, Reginster J-Y. Management of osteoporosis of the oldest old. Osteoporos Int. 2014;25(11):2507–29. https://doi.org/10.1007/s00198-014-2755-9.

    Article  PubMed  CAS  Google Scholar 

  • Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Glucocorticoid- Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. NEJM. 1998;339:292–9. https://doi.org/10.1056/NEJM199807303390502.

    Article  PubMed  CAS  Google Scholar 

  • Shoback D, Rosen CJ, Black DM, Cheung AM, Hassan Murad M, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab. 2020;105(3):dgaa048. https://doi.org/10.1210/clinem/dgaa048.

    Article  PubMed  Google Scholar 

  • Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923e34. https://doi.org/10.1359/jbmr.080710.

    Article  Google Scholar 

  • Silverman SL, Chines AA, Kendler DL, Kung AWC, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, Bazedoxifene Study Group. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int. 2012;23:351e63. https://doi.org/10.1007/s00198-011-1691-1.

    Article  CAS  Google Scholar 

  • Tadrous M, Wong L, Mamdani MM, Juurlink DN, Krahn MD, Levesque LE, Cadarette SM. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network me- ta-analysis. Osteoporos Int. 2014;25:1225–35. https://doi.org/10.1007/s00198-013-2576-2.

    Article  PubMed  CAS  Google Scholar 

  • Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Fink Eriksen E, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11e7. https://doi.org/10.1016/j.bone.2017.08.003.

    Article  Google Scholar 

  • Umland EM, Karel L, Santoro N. Bazedoxifene and conjugated equine estrogen: a combination product for the management of vasomotor symptoms and osteoporosis prevention associated with menopause. Pharmacotherapy. 2016;36:548e61. https://doi.org/10.1002/phar.1749.

    Article  CAS  Google Scholar 

  • de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris BJP. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int. 2011;22:567e76. https://doi.org/10.1007/s00198-010-1302-6.

    Article  CAS  Google Scholar 

  • Wolfe F, Bolster MB, O’Connor CM, Michaud K, Lyles KW, Colón-Emeric CS. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res. 2013;28:984e91. https://doi.org/10.1002/jbmr.1792.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Metabolic Diseases Unit, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy

    Gemma Marcucci

Authors
  1. Gemma Marcucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gemma Marcucci .

Editor information

Editors and Affiliations

  1. DCMT, University of Florence, Florence, Italy

    Maria Luisa Brandi

  2. Endocrinology and Metabolism, McMaster University Medical Centre, Oakville, ON, Canada

    Aliya Khan

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Marcucci, G. (2024). Antiresorptive Drugs’ Role in Management of Postmenopausal Osteoporosis. In: Brandi, M.L., Khan, A. (eds) Bone Metabolism, Parathyroid Glands, and Calciotropic Hormones. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-030-19632-5_13-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-19632-5_13-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-19632-5

  • Online ISBN: 978-3-030-19632-5

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation